They sit in different categories because coverage is written against approved indications and benefit design, not against molecules. Semaglutide is marketed as separate products for glycaemic control, for weight management, and for cardiovascular risk reduction in specific populations, each with its own label, its own maximum dose, and its own place on the formulary — and a plan that excludes weight-loss drugs is excluding a benefit category, not a chemical.
The two criteria sets look genuinely different.
| T2DM pathway | Obesity pathway |
|---|
| Anchor criterion | Diagnosis plus a glycaemic parameter (A1c above target, or on-treatment) | BMI threshold, with or without comorbidity |
| Typical step | Metformin trial or documented intolerance/contraindication; sometimes a preferred GLP-1 first | Lifestyle intervention for 3–6 months; sometimes a preferred agent first |
| Lifestyle documentation | Rarely required as a hard gate | Almost always required |
| Reauthorisation test | A1c response or continued need | Percentage weight loss, commonly ≥5% |
| Benefit exclusion risk | Low; treating diabetes is a core covered benefit | High; many plan documents exclude weight-loss pharmacotherapy entirely |
| Max labelled dose | Lower for the diabetes product of the same molecule | Higher |
What counts as failing a step. Three things all count and they are not equally easy to document:
- Inadequate response — an adequate trial at an adequate dose for an adequate duration with the target unmet. Reviewers want the dose, the duration and the on-treatment lab value. "Tried metformin, didn't work" fails; "metformin 1,000 mg twice daily from January, A1c 6.9% in May" passes.
- Intolerance — the named drug, the named adverse effect, the date, and ideally what was tried to mitigate it. For metformin, note whether extended-release was attempted, because reviewers ask.
- Contraindication — the cleanest of the three, because it is usually a single objective fact such as an eGFR value below the labelled threshold.
Where your cardiovascular history becomes leverage. On the diabetes side there is a body of outcome evidence that criteria writers respond to: SUSTAIN 6 showed a reduction in major adverse cardiovascular events with semaglutide in type 2 diabetes at high cardiovascular risk [1], FLOW showed reduced kidney-disease progression and cardiovascular death in T2DM with chronic kidney disease [2], and SELECT extended cardiovascular benefit to people with overweight or obesity and established cardiovascular disease but without diabetes [3]. SELECT is the reason a third pathway now exists in many formularies: cardiovascular risk reduction, which is neither the diabetes criteria set nor the weight criteria set. If your plan has that pathway, established cardiovascular disease is the entry key — family history alone is not.
On dose. Yes, this has a real consequence. The diabetes product of a molecule is labelled to a lower maximum than the obesity product, and quantity-limit edits are written to the label. An approval under the diabetes pathway will generally not authorise the higher obesity maintenance dose, and requests that try tend to be denied on quantity rather than necessity. That is a dose-appropriateness conversation for your prescriber, not something to work around administratively.
7The three-pathway framing is right. Our plan added the CV pathway last cycle and nobody on the front line knows it exists. – lipid_panel_q 7 months ago add a comment